• Molecular Partners AG, of Zurich, Swizterland, said results from a Phase I/II study published in the American Journal of Ophthalmology showed that MP0112, a long-acting anti-VEGF DARPin, was found to be safe in patients with diabetic macular edema and showed suppression of VEGF-A concentrations in aqueous humor after a single intraocular injection, with a pharmacokinetic half-life of about two weeks.